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 Pharmacological activation of the 5-HT1B and 1A receptors has been 
implicated in OCD-like behaviors in rodents such as increased perseverative 
circling, checking behaviors, and locomotor stereotypy. However, little is 
understood about the effects of 5-HT1B and 1A receptor activation on behavioral 
inflexibility, a common symptom associated with OCD. The present study utilized 
the 5-HT1B/1A receptor agonist RU24969 at 0.01, 0.1, and 1.0 mg/kg to test 
three hypotheses. The first hypothesis predicted RU24969 would lead to a dose-
dependent impairment on behavioral flexibility in C57BL/6J mice. It was also 
predicted that male C57BL/6J mice would be more inflexible than female 
C57BL/6J mice following RU24969 administration. The second hypothesis stated 
that RU24969 would have a dose-dependent increase in locomotor activity. 
Finally, it was hypothesized that RU24969 would increase anxiety-like behaviors 
in C57BL/6J mice. Results concluded that male mice had impaired behavioral 
flexibility at all doses of RU24969 while female mice were only impaired at the 
1.0 mg/kg dose. For locomotor activity, male mice exhibited reduced distance 
traveled at the 1.0 mg/kg dose while RU24969 had no significant effect on female 
locomotion scores. Finally, male mice exhibited greater anxiety-like behaviors at 
0.1 and 1.0 mg/kg while female mice were not significantly affected. Overall, the 
evidence suggests that 5-HT1B and 1A receptor activation could play a role in 
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Obsessive-compulsive disorder (OCD) is characterized by insistent urges, 
persistent thoughts, and/or repetitive behaviors that are resistant to inhibition 
(APA, 2013). OCD is the fourth most common mental disorder with estimates of 
3% of the adult population currently afflicted (Centers for Disease Control and 
Prevention [CDC], 2019; Kessler et al., 2005). According to the National Institute 
of Mental Health (NIMH) (2019), it is estimated that OCD affects one in a 
hundred adults in the United States, with a higher prevalence in women at 1.8% 
compared to men at 0.5%, although, men are more commonly diagnosed with 
childhood OCD (APA, 2013). Roughly 85% of adults diagnosed in the United 
States report experiencing moderate to severe symptoms (Alegria et al., 2007). 
OCD also has a relatively high comorbidity rate with disorders such as Tourettes 
(APA, 2013; Browne et al., 2014). According to the most recent 2003 survey of 
OCD lifetime prevalence rates, OCD was most prevalent in adults (1.5%) aged 
18-29 and remains prevalent throughout the lifespan with the lowest rates (0.5%) 
in adults over the age of 60 (Alegria et al., 2007; NIMH, 2019). Given that 
obsessive-compulsive symptoms are seen in as high as 20% of the general 
population (Fullana et al., 2009), continued efforts to understand the mechanisms 
of OCD are needed. 
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Current research suggests that genetic factors directly impact the onset of 
OCD. Studies have shown significantly higher rates of OCD among monozygotic 
twins compared to dizygotic twins (Browne, et al., 2014; Eley, et al., 2003). The 
evidence points to genetic factors for the development of OCD because 
monozygotic twins share the same genetic code; thus, the prevalence of OCD is 
higher. Amongst families, the likelihood of inheriting OCD is 50% (Browne, et al., 
2014; Mataix-Cols et al., 2013), although environmental factors such as early 
childhood stress (Adams et al., 2018) and trauma (Badour et al., 2012) have 
been associated with the development of OCD symptoms. 
Over time, behavioral theories of anxiety have attempted to explain both 
the obsessive and compulsive characteristics that underlie the development, 
maintenance, and treatment of OCD. The current theory suggests that OCD is 
brought about by the misattribution of fearful thoughts/feelings to an otherwise 
neutral stimulus (D'Alessandro, 2009; Kagan et al., 2017). Moreover, a fear 
response to related and objectively non-threatening stimuli is conditioned over 
time. Compulsions then develop as a behavior to alleviate the anxious feelings 
toward potential fear-inducing stimuli. At a foundational level, it is evident that 
OCD behaviors are a learned response in an attempt to alleviate anxiety which is 
conditioned throughout development, to the extent that maladaptive compulsions 
and repetitive behaviors are formed. Moreover, the urge to suppress anxious 
feelings is reinforced by decreasing anxiety.  
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In the most recent fifth edition of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-V), OCD is considered an anxiety-related disorder by 
which intrusive obsessions can cause an abnormal increase in anxiety or distress 
(APA, 2013). To suppress obsessive thoughts, urges, or images, the individual 
will perform a compulsive behavior (thoughts and/or actions). OCD has a direct 
impact on the quality of life by which obsessions and compulsions create social 
and/or occupational hurdles that are difficult to overcome (APA, 2013) and 
treatment options are limited to anti-depressant medications and cognitive 
behavioral therapy (Hirschtritt et al., 2017). Along with the psychological 
determinants of OCD, there are also various neurological theories (structural and 
functional) explaining the onset and maintenance of OCD that have increased in 
validity. Neuroimaging studies suggest cortico-striato-thalamo-cortical (CSTC) 
network dysfunction is thought to be primarily responsible for the neurological 
basis of OCD (Gao et al., 2019; Posner et al., 2014; Tang et al., 2016). This 
network is made up of many brain areas and thus further study is needed to 
further elucidate specific areas of the network that are responsible for OCD 
pathology.  
OCD is a debilitating and prevalent disorder. Current theory suggests that 
OCD’s grounding in anxiety is the reason compulsive symptoms are acquired 
and maintained. OCD harms an individual’s quality of life as obsessions and 
compulsions can not only be maladaptive for the person with the disorder, but for 
the people around them as well. Treatment options are limited, yet much can be 
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learned by studying the neural components that influence obsessive and 
compulsive behaviors. Further study of the neurological mechanisms behind 





NEUROLOGICAL BASIS OF OBSESSIVE-COMPULSIVE DISORDER 
 
Many studies have aimed to understand the neurological determinants of 
OCD. Prior to the utilization of neuroimaging which highlights possible brain 
areas responsible for OCD symptoms, pathophysiological studies pointed to the 
orbitofrontal cortex (OFC) and basal ganglia as areas most likely involved with 
OCD. With measurements of positron emission tomography (PET), magnetic 
resonance imaging (MRI), and functional MRI (fMRI), previous theories 
speculated increased activity in the frontal cortex, including OFC, anterior 
cingulate cortex (ACC), caudate nucleus, and thalamus (Baxter, et al., 1987; 
Swedo, et al., 1989; Zohar, et al., 1989). There is also evidence to suggest that 
OCD patients have differing OFC, hippocampus, and amygdala volumes 
compared to healthy controls (Atmaca et al., 2008; Kwon et al., 2003; Rao et al., 
2018; Szeszko et al., 1999).  These imaging studies further demonstrate that 
OCD is most likely attributed to several brain areas or circuits and not a single 
brain region. More recent evidence suggests the cortico-striato-thalamo-cortical 
(CSTC) circuit is involved in the pathophysiology of OCD, as this circuit has been 
implicated in the disruption of response inhibition and goal-oriented behaviors 
(Rao, et al., 2018). The OFC, caudate, thalamus (Nakao, et al., 2014), and 
hippocampus (Rao, et al., 2018) are among brain regions that had show 
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structural changes relating to OCD diagnosis. Thus, these brain regions are of 
particular interest when investigating the neural correlates of OCD.      
The OFC is among the most commonly discussed brain regions implicated 
in OCD. The OFC is responsible for executive and spatial cognition (Bryden & 
Roesch, 2015; Robbins, 2000) including flexible learning and goal-directed 
learning (Lei et al., 2018; Sadacca et al., 2017). The OFC is of particular interest 
as patients with damage to the OFC show a similar OCD-like phenotype 
including impairments in cognitive flexibility (Fellows & Farah, 2003; Ghahremani 
et al., 2010) and excessive rumination (Grados, et al., 2008). In addition, 
pediatric OCD patients have abnormally large right OFC white matter volume 
(Macmaster et al., 2010) and in general, have larger white matter volumes 
throughout the brain (Atamaca, et al., 2008). Imaging studies show that the OFC 
is hyperactive in patients with OCD compared to healthy controls (Lagemann, et 
al., 2012). In mice, induced hyperactivity in the OFC is associated with 
impairments in behavioral flexibility (Longo, et al., 2018). Overall, a large and 
hyperactive OFC seems to explain symptoms related to OCD from a neurological 
perspective.  
The hippocampus is also viewed as having a mediating role in the 
neurological mechanisms of OCD, although, neuroimaging studies show 
conflicting results regarding the neural correlates in OCD. It has been 
demonstrated that there is increased left hippocampal volume in patients with 
OCD compared to healthy controls (Kwon, et al., 2003; Rao, et al., 2018). Also, 
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recent evidence suggests a negative correlation between left hippocampal 
volume and rates of compulsivity, with larger volumes associated with higher 
compulsivity ratings (Rao, et al., 2018). In opposition, reductions in bilateral 
hippocampal volume in OCD patients compared to controls have been reported 
in various studies (Atamaca, et al., 2008; Szeszko, et al., 1999). These 
conflicting findings may be due to differences in pharmacological effects or 
unknown comorbidity with other disorders. One meta-analysis points out that 
patients with OCD and reduced hippocampus volume were also shown to 
simultaneously be receiving pharmacological treatment before neural testing 
(Boedhoe et al., 2016). This may suggest that larger hippocampal volumes are 
attributed to untreated OCD and that a reduction in hippocampal volume in OCD 
individuals is due to pharmacological treatment. In mice, lesions of the 
hippocampus are shown to increase behavioral rigidity as found with impaired 
reversal learning performance in different spatial tests (Bardgett, et al., 2003; 
Kleinknecht, et al., 2012; Rossi, et al., 2012) suggesting that the hippocampus is 
important for cognitive flexibility and that abnormalities to the hippocampus can 
increase habit formation.  
In fMRI tests, the ACC and caudate have also been implicated in OCD 
etiology. The dorsal ACC (dACC), which is responsible for reward processing 
and decision making (Bush, et al., 2000), is shown to have increased functional 
connectivity to the caudate in unmedicated OCD patients. The dACC has also 
been shown to be positively correlated with compulsion scores on the Yale-
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Brown Obsessive-Compulsive Scale (Y-BOCS) (Zhang, et al., 2017). Higher 
connectivity between the dACC and caudate compared to healthy controls may 
be a clinical indicator of OCD. While it has also been reported that there is 
increased activation between the dACC and prefrontal cortex (PFC) (Yun, et al., 
2017). Both network pathways are included in the CSTC circuit which has been 
repeatedly implicated in the expression of OCD symptoms. Also, activation of the 
dACC is shown to facilitate fear-conditioned learning (Phelps, et al., 2004) which 
is thought to significantly contribute to OCD compulsions, while lesions in 
humans lead to a reduction in OCD symptoms (Dougherty, et al., 2002) further 
implicating the dACC in OCD pathology. Overall, the results indicate that 
abnormalities in the circuitry between the ACC and caudate are a part of the 
neural alteration that contributes to OCD.  
Neurobiological models of OCD continue to suggest that a malfunctioning 
CSTC network is involved in the manifestation of OCD and its symptoms 
(Menzies, et al., 2008; Saxena, et al., 1998). The CSTC circuit includes the OFC, 
thalamus, and striatum (Saxena, et al., 1998), all of which communicate during 
goal/reward-oriented learning (Bradfield & Balleine, 2017). Using optogenetics, 
repeated activation over days of the OFC and ventromedial striatum has been 
shown to elicit OCD-like behaviors in mice; specifically, repetitive grooming 
behaviors (Ahmari, et al., 2013). However, it is worth noting that acute activation 
did not increase grooming behavior and that to elicit increases in grooming 
behavior repeated activation was required (Ahmari, et al., 2013). This suggests 
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that the onset of OCD could be the result of chronic repeating hyperactivation. 
There is also evidence to suggest that severing the connection between the 
thalamus and dorsomedial striatum (DMS) impairs reversal learning in rats 
(Bradfield & Balleine, 2017). Rats with lesions to the thalamus-DMS pathway 
after the acquisition of a spatial task performed worse after the initial acquisition 
yet performed similarly to control rats after a second training session (Bradfield & 
Balliene, 2017). This indicates that the thalamus-DMS pathway may modulate 
behavioral flexibility. Thus, the CSTC network is important for behavioral 
flexibility and a dysfunctional CSTC network may lead to impairments in 
behavioral flexibility which could explain one of OCD’s core symptoms.  
The CSTC is commonly divided into two networks called “loops.” These 
are the direct and indirect CSTC loops, in which studies have demonstrated that 
OCD symptoms can be attributed to each loop (Mataix-Cols & van den Heuvel, 
2006; Saxena et al., 1998; Saxena & Rauch, 2000). Specifically, the direct loop is 
responsible for the initiation and continuation of behaviors, while the indirect loop 
is responsible for inhibiting and changing between behaviors (Mataix-Cols & van 
den Heuvel, 2006). Therefore, difficulty inhibiting repetitive behaviors may stem 
from issues with the CSTC circuit. In mice, activation of the CSTC circuit using a 
soluble cytokine receptor agonist-induced repetitive head “bobbing” and 
increased locomotor behaviors (Patel et al., 2012). This is supported by the later 
finding from Ahmari, et al. (2013) that optogenetic stimulation of the CSTC 
regions increased repetitive grooming behaviors in mice. Hyperactivation of the 
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CSTC neural loop seems to be a factor for increased OCD-like behaviors in 
rodents, although, little is understood about the relationship between this CSTC 
network and behavioral flexibility.     
The neurological basis for OCD is quite complex. What is known is that 
several brain regions and circuits are involved. Irregularities in the CSTC network 
seem to have the most influence on the manifestation of OCD symptoms, such 
as excessive grooming and impaired reversal learning in rodents. This, in part, 
seems to be due to the CSTCs involvement with goal-directed learning. Thus, 
issues with the CSTC network, such as hyperactivation, could contribute to some 
of the goal-directed learning impairments like behavioral inflexibility. Overall, 
structural and functional abnormalities to the CSTC network of brain areas seem 






SYMPTOMS AND TREATMENTS OF OBSESSIVE-COMPULSIVE DISORDER 
 
OCD presents itself in many ways and symptoms that range in severity. It 
is believed that obsessions and compulsions do not co-occur; instead, they occur 
one after the other (Laposa et al., 2019). Also, the DSM-5 indicates that some 
patients with OCD can experience solely obsessions or compulsions, while both 
do not need to be present for diagnosis (APA, 2013). Research looking into the 
symptomology of OCD has identified five separate dimensions of symptoms: 
obsessions with contamination/cleaning, symmetry/ordering, doubt/checking 
behaviors, intrusive and unacceptable thoughts, and hoarding (APA, 2013; 
Brakoulias et al., 2013). Due to underlying anxiety, symptoms are often 
debilitating and individuals with clinically diagnosed OCD often require 
pharmacological and/or psychological interventions. Treating OCD is sometimes 
difficult due to the wide range of symptoms and the lack of available 
interventions. The most common treatment for OCD is co-administration of a 
selective serotonin reuptake inhibitor (SSRI) to treat the underlying anxiety and 
cognitive behavioral therapy (CBT) to address maladaptive and habitual 
behaviors that impair everyday functioning (Hirschtritt et al., 2017). However, this 
treatment combination is lacking, as it is a general treatment option for most 
anxiety-related disorders and thus does not specifically address the obsessive 
and compulsive symptoms solely attributed to OCD.  
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Maladaptive fear conditioning leads to obsessive behaviors and excessive 
habit formation, which are some of the core symptoms of OCD. Habits are 
formed from repeating behavioral actions over time. Habits can become 
excessive, leading to disruptions in daily living, which is a core symptom of OCD 
(APA, 2013). Excessive habit formation can have negative implications for 
individuals inflicted with OCD and can be seen in both humans and animals 
(Gillan & Sahakian, 2015; Hadjas et al., 2019). Under normal circumstances in 
healthy individuals, habits result in automatic responses to various stimuli even if 
the response does not provide a favorable outcome (Dickinson, 1985). This 
automatic response can cause individuals with OCD to disregard goal-oriented 
behaviors in favor of appetitive behaviors (Gillan et al., 2011) which is thought to 
be a result of the underlying anxiety that OCD entails (Eysenck et al., 2007). It is 
demonstrated that patients with OCD are more prone to habit formation of 
avoidance behaviors compared to controls (Gillan et al., 2014). Since habit 
formation and behavioral flexibility are modulated by the same brain areas, 
issues with excessive habit formation may create impairments in flexibility. 
Excessive habit formation is also seen in genetic mouse models of OCD 
compared to healthy wild-type littermates (Hadjas et al., 2019). Also noted was 
an impairment in behavioral flexibility, which was believed to be a result of 
excessive habit formation (Hadjas et al., 2019). Tasks like the Wisconsin Card 
Sorting Task (WCST) and other reversal learning tasks recruit the OFC to help 
adapt to differing contingencies (Bechara et al., 2000). Compulsivity scores have 
13 
 
been linked with a lack of connectivity throughout the OFC (Meunier et al., 2012) 
and since patients with OCD often display neurological abnormalities in the OFC 
(MacMaster et al., 2010), deficits in behavioral flexibility have been associated 
with compulsivity (Izquierdo & Jentsch, 2012). Also, rodent studies have shown 
deficits in the OFC and striatum to induce behavioral inflexibility (Izquierdo & 
Jentsch, 2012). Overall, behavioral flexibility utilizes areas of the brain that are 
shown to be dysfunctional in OCD suggesting that compulsivity and impairments 
to behavioral flexibility are related. The evidence seems to indicate that 
excessive habit formation creates problems with the ability to be flexible in 
cognition and behavior. 
Compulsions are an attempt to alleviate anxious feelings that are related 
to the obsessive symptoms in OCD and usually include a ritual that is performed 
repetitively (APA, 2013; Laposa et al., 2019). Repetitive and maladaptive 
behaviors are often non-voluntary in which the patient feels forced to carry out a 
behavior (Robbins et al., 2012). It is also noted that in some cases, compulsive 
behaviors manifest first in which anxiety becomes a byproduct while in other 
cases, anxiety is the precursor to compulsivity (Kashyap et al., 2012; Robbins et 
al., 2012). OCD’s underlying anxiety symptoms seem to vary, making it difficult to 
understand whether anxiety is the root cause or a result of OCD. Much is still 
unknown about the impact of OCD on cognition. Understanding the types of 
cognitive deficits related to OCD assists with discovering treatment options for 
individuals afflicted with this disorder. 
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The most common pharmacological intervention for treating OCD is the 
use of SSRIs. According to the American Psychiatric Association, they are used 
as a treatment and have demonstrated efficacy in many patients by reducing 
symptom severity (Koran et al., 2007). A more recent meta-analysis analyzing 
placebo-based clinical trials using SSRIs shows that SSRIs begin to be effective 
around week six of treatment with most patients reporting SSRIs effectiveness by 
at least week 12 of treatment (Issari et al., 2016). A commonly used SSRI also 
used to treat depression, fluoxetine, has shown in a clinical trial to remain 
effective at reducing OCD symptoms (Tural et al., 2019). Improvements in OCD-
like symptoms such as repetitive grooming have also been shown in genetically 
induced mouse models of OCD (Ahmari et al., 2013; Ullrich et al., 2018). Chronic 
fluoxetine treatment has also been shown to alleviate obsessive-compulsive 
behaviors in mice with pharmacologically induced OCD (Ho et al., 2016; Woehrle 
et al., 2013). SSRIs seem to be the most effective pharmacological treatment 
currently available. However, these treatments are not perfect solutions as SSRIs 
target the brain’s serotonin levels as a whole instead of acting on specific neural 
targets. It is shown in rodents that certain 5-HT receptor targets may be 
responsible for OCD-like behaviors. For example, one study concluded that 
activation of the 5-HT1B receptor was responsible for inducing impairments in 
delayed alternation, a test of spatial working memory, and that administration of 
fluoxetine was able to alleviate the deficits as a result (Woehrle et al., 2013). This 
example demonstrates that specific serotonergic receptors may be implicated in 
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some of the cognitive impairments associated with OCD in humans and that the 
SSRI fluoxetine may alleviate deficits in cognition by inhibiting 5-HT1B receptors.  
OCD has many different symptoms, some of which impact cognition in 
various ways. However, some of these cognitive deficits related to OCD are not 
widely understood. Since pharmacological options like SSRIs are an important 
tool used alongside behavioral therapy for treating OCD, the need for novel 
treatments is high. Further, OCD does not have specific pharmacological 
therapies designed to treat its unique symptomatic profile. SSRIs are a common 
pharmacological therapy for various psychiatric disorders including depression, 
schizophrenia, and autism spectrum disorder  (ASD) which leaves much to be 
gained from discovering novel pharmacological therapies that are specific to 
OCD and other related disorders. To do this, further investigation of the 
serotonergic neurotransmitter system would be beneficial so that patients with 







SEROTONIN IN OBSESSIVE-COMPULSIVE DISORDER 
 
As discussed in Chapter Three, the most common pharmacological 
therapy for treating OCD is a selective serotonin reuptake inhibitor (SSRI). SSRIs 
are primarily used as an anxiolytic or antidepressant. These compounds work by 
inhibiting the process of serotonin reuptake to effectively increase serotonin in 
the brain. While SSRIs like fluoxetine are effective at reducing OCD symptoms, 
they cannot target specific receptors that may be responsible for some of OCD’s 
most prominent symptoms. A more effective pharmacological approach would be 
to target specific serotonin receptors that are implicated with specific OCD 
impairments. The current study focuses on typical memory impairments 
associated with OCD such as behavioral inflexibility, as well as anxious and 
repetitive behaviors, and how they are affected by serotonin receptor modulation. 
It is necessary to identify specific serotonergic targets related to OCD so that 
future pharmacology can develop novel treatments for OCD-related symptoms.   
 Serotonergic neurons are relatively limited throughout the brain, and in 
general, seem to have a large influence on mood, emotion, and sleep (Bear et 
al., 2016), as well as various cognitive functions (Vadodaria et al., 2018). 
Serotonin (5-hydroxytryptamine, 5-HT) is a ligand in the amine group of 
neurotransmitters and is derived from the amino acid tryptophan which enters the 
brain via blood. Ultimately, tryptophan enters the bloodstream via the gut, as it is 
consumed via various meats and dairy products (Bear et al., 2016; Vadodaria et 
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al., 2018). Tryptophan is converted to 5-hydroxytryptophan which is then 
converted to 5-hydroxytryptamine (Jonnakuty & Gragnoli, 2008). This process is 
essential for providing the central nervous system with serotonin. Once 5-HT is 
excreted into the synaptic cleft during synaptic transmission, excess 5-HT is 
transported back into the neuron to be recycled and used in future synaptic 
transmissions (Bear et al., 2016). The process of 5-HT reuptake is important for 
efficiency and to prevent wasted neurotransmitter. However, excessive reuptake 
of 5-HT can have negative implications.  
5-HT is an important neurotransmitter in the brain, and since there is such 
a small amount in the central nervous system, small alterations to 5-HT levels 
can have significant effects. Some of the implications of altered 5-HT levels are 
negative. A lack of 5-HT is thought to be associated with increased anxiety 
symptoms such as a lack of perceived control and increased interfering thoughts 
(Hood et al., 2017).  
This suggests that decreased 5-HT is related to anxiety, but not 
depression. Since SSRIs increase overall serotonin levels in the brain, SSRIs are 
a common treatment option for individuals with anxiety, especially OCD-related 
anxiety (Albert et al., 2019; Hirschtritt et al., 2017; Romanelli et al., 2014). SSRIs 
are an important and effective treatment option for individuals afflicted by anxiety 
disorders like OCD. However, due to the pharmacodynamics of SSRIs, the full 
extent of their effectiveness is unknown. Consequently, there are mixed findings 
on the effectiveness of SSRIs when treating anxiety.  
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The anxiolytic effects of SSRIs seem to differ in the literature. Some 
results indicate SSRIs act as an anxiolytic. Specifically, rats given fluoxetine had 
reduced immobility time in the tail suspension test (Kamei et al., 2003). Also, 
mouse pups separated early from the dam exhibited less anxiety-like symptoms 
as evidenced by decreased ultrasonic vocalization from the pups treated with 
fluoxetine (Fish et al., 2004). However, another study demonstrated that 
increased levels of anxiety in rats (such as someone with an anxiety disorder) 
resulted in anxiogenic effects following treatment with the SSRI escitalopram as 
evidenced by increased startle response in an acoustic startle paradigm 
(Pettersson et al., 2015). In another study, escitalopram and fluoxetine both 
showed an anxiogenic effect in rats as evidenced by increased latency in an 
open field during a novelty suppressed feeding test and fluoxetine administration 
acted as an anxiogenic as evidenced by less time spent in the open arm during 
an elevated plus-maze task (Turcotte-Cardin et al., 2019). Although, Turcotte-
Cardin et al. (2019) found anxiogenic effects of SSRI administration in 5-HT1A 
receptor knockout rats which suggested that 5-HT1A receptors are somewhat 
responsible for the paradoxical effects related to SSRI and anxiety. While SSRIs 
are shown to have mixed effects in reducing anxiety symptoms, it is important to 
understand the cognitive effects of SSRIs as well. 
The cognitive effects of SSRIs are important as many psychiatric 
disorders including OCD result in cognitive impairment. It has been noted that 
OCD specifically can result in impairments to behavioral flexibility (Hadjas et al., 
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2019; Izquierdo & Jentsch, 2012). Therefore, effective pharmacological treatment 
for OCD would assist in reducing cognitive impairment. However, the SSRI 
fluoxetine was shown to impair reversal learning in attention deficit hyperactivity 
disorder (ADHD) patients but not ASD patients compared to controls; specifically, 
patients with ADHD receiving fluoxetine committed more perseverative errors 
than controls (Chantiluke et al., 2015). SSRIs may be treating only certain 
symptoms and exacerbating others. These findings further support the need to 
investigate 5-HT receptor modulation as a novel pharmacological treatment for 
OCD.   
One potential target is the 5-HT1A receptor. The 5-HT1A receptor has 
been identified as a potential 5-HT receptor subtype that is involved in the 
effectiveness of anti-obsessive-compulsive drugs (Lesch et al., 1991). The 5-
HT1A receptor is inhibitory causing downregulation of 5-HT neuron activity and 
becomes desensitized following chronic SSRI usage (Turcotte-Cardin et al., 
2019). Essentially, the inactivation of 5-HT1A receptors should increase neuronal 
activity in 5-HT neurons. Also, 5-HT1A post-synaptic receptors are mostly 
located in the hippocampus (Lesch et al., 1991) but they are also expressed in 
the PFC (Puig & Gulledge, 2011) which may suggest that modulation of 5-HT1A 
receptors could have cognitive effects such to that of behavioral flexibility, a core 
symptom of OCD.  
Effective pharmacological treatment for OCD would ideally target multiple 
receptor sites attributed to core symptoms like behavioral flexibility and anxiety. 
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Another target worth investigating is the 5-HT1B receptor. The 5-HT1B receptor 
has been identified as a modulator of anxiety disorders and impulsive behaviors 
(Kent et al., 2002). More importantly, 5-HT1B receptors are dispersed throughout 
the midbrain with a significant concentration in the hippocampus and caudate 
(Bonaventure et al., 1997; Kent et al., 2002). Using PET imaging, the 5-HT1B 
receptor has been shown to have increased binding in OCD patients that 
displayed deficits in pre-pulse inhibition (Pittenger et al., 2016). This suggests 
that some of OCDs symptoms could stem from excess 5-HT1B receptor binding. 
Also, chronic SSRI treatments reduce OCD-like behaviors induced by 5-HT1B 
receptor activation in the OFC of mice (Shanahan et al., 2011). Further, 5-HT1B 
receptor activation can induce OCD-like deficits such as hyperlocomotion which 
was attenuated by chronic SSRI treatment (Shanahan et al., 2009). This 
evidence adds support for the investigation of the 5-HT1B receptor since SSRIs 
seem to rescue 5-HT1B receptor activation-induced OCD-like behaviors in 
rodents.  
Overall, the serotonergic system is implicated in the pathophysiology of 
OCD in both humans and animals. While SSRIs are the pharmacological 
treatment of choice for patients with OCD, SSRIs can have unpredictable effects, 
and in some cases, can exacerbate impairments to cognitive abilities such as 
behavioral flexibility. The paradoxical effects of SSRIs make novel 
pharmacological treatments a primary concern. As mentioned, modulation of 5-
HT1A and 1B receptors demonstrate an association with OCD symptoms which 
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makes them interesting targets for investigation. To study the behavioral effects 
of 5-HT1A and 1B modulation, animal models are necessary to draw parallels to 





ANIMAL MODELS OF OBSESSIVE-COMPULSIVE DISORDER 
 
Understanding the altered neural function behind OCD would enable more 
effective treatment options to become available. Current treatment options are 
limited, and their effectiveness is not reliable. OCD is commonly studied in 
humans using existing and/or novel test measurements that probe individuals’ 
levels of OCD behaviors and associate these measurements with other variables 
like regional brain activity and structural brain imaging. Essentially, the research 
attempts to find brain differences in patients with distinctive OCD subtypes 
(clinical OCD, non-clinical OCD, self-diagnosed OCD, etc.) compared with 
healthy non-OCD individuals. Clinical trials enable researchers to evaluate novel 
pharmacological treatments for OCD and measure whether the treatments 
effectively reduce OCD symptoms. Certain species express translational 
behaviors that are widely accepted as analogs to OCD in humans. This allows for 
the utilization of animal models of OCD as a proxy for understanding OCD in 
humans.  
Animal models of OCD are an effective method of understanding the 
neural and biological mechanisms behind OCD. Behavioral inflexibility is one 
symptom of OCD that is commonly measured in both humans (Gruner & 
Pittenger, 2017; Lucey, et al., 1997) and animals (Boom, et al., 2019; Eilam, et 
al., 2012). One prominent measure of behavioral flexibility in humans is the 
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Wisconsin Card Sorting Task (WCST) which specifically measures the ability to 
adapt behavior in response to shifting rules and patterns (Bizon, et al., 2012). 
Different studies across age groups using the WCST have shown that individuals 
with OCD make more perseverative errors and require more trials compared with 
healthy matched controls (Lucey, et al., 1997; Min-Sup, et al., 2008; Yazdi-
Ravandi, et al., 2018) and that increases in obsessional beliefs tend to 
exacerbate errors (Bradbury, et al., 2011). In addition, a genetic rodent model of 
OCD similarly showed that flexibility was impaired as evidenced by impaired 
reversal learning performance (Boom, et al., 2019). The parallels between 
individuals with OCD and rodent models of OCD in behavioral flexibility support 
further examinations utilizing rodent models of OCD. While there are apparent 
similarities in flexibility between humans and rodents, another symptom of OCD 
that is important to address is anxiety. 
Pharmacological models of OCD most commonly use dopaminergic or 
serotonergic system modulation to elicit OCD-like behaviors in rodents as a 
method of understanding behavioral outcomes linked to these systems. There 
are a variety of possible 5-HT receptor targets useful for understanding OCD at a 
neurobiological level. Acute administration of the 5-HT1A receptor agonist 8-OH-
DPAT reduced alternation ratios in male C57BL/6J mice (Odland, Jessen, 
Fitzpatrick, et al., 2019; Odland, Jessen, Kristensen, et al., 2019) which suggests 
that activation of 5-HT1A receptors induces compulsive-like behaviors. Also, 
using an open-field test, 8-OH-DPAT was shown to increase compulsive-like 
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checking behaviors in male rats (Alkhatib et al., 2013). Rats that received the 5-
HT1A agonist would repeatedly return to specific areas of the open field which is 
similar to OCD-like checking behaviors in humans. Therefore, 5-HT1A receptor 
activation may be responsible for compulsive behaviors in male rodents. Studies 
showing the effects of 5-HT1B agonism on OCD-like behaviors in rodents are 
lacking. However, 5-HT1B agonist-induced mouse models of OCD are also seen 
to be effective. 
One relatively novel 5-HT receptor target for investigating OCD behaviors 
in mice is the 5-HT1B receptor. Serotonin 1B receptor activation is shown to 
increase locomotor behaviors and produce deficits to PPI and delayed alternation 
(Shanahan et al., 2009, 2011; Woehrle et al., 2013), all of which are relevant 
OCD-like behaviors. Acute treatment with the 5-HT1B/1A receptor agonist 
RU24969 in female C57BL/6J mice increases PPI (Dulawa & Geyer, 2000). Also, 
acute administration of RU24969, a 5-HT1B/1A receptor agonist, at relatively 
high doses (1-10 mg/kg) is shown to increase the total distance traveled in an 
open field test in female C57BL/6J mice (Ho et al., 2016; Shanahan et al., 2009). 
However, the direct effects of 5-HT1B/1A activation on behavioral flexibility are 
not understood. 5-HT1B and 1A activation seem to induce OCD-like behaviors in 
mice making them novel targets of interest for studying the neurobiology of 





SUMMARY AND HYPOTHESES 
 
OCD’s symptomology includes excessive habit formation which could lead 
to impairments in goal-directed learning and behavioral flexibility (Gruner & 
Pittenger, 2017). Neuroimaging studies have highlighted the involvement of the  
OFC in the expression of  OCD symptoms (Menzies et al., 2008). OFC lesion 
studies have also found impairments to probabilistic reversal learning, a measure 
of behavioral flexibility in animals (Chang, 2014; Chase et al., 2012). Previous 
studies using direct co-administration of a 5-HT1B agonist and antagonist into 
the OFC of mice demonstrated that the 5-HT1B receptors in the OFC are 
necessary to produce perseverative circling behaviors in an open field 
(Shanahan et al., 2009, 2011). The 5-HT1B/1A receptor agonist RU24969 has 
been shown to induce OCD-like behaviors in mice, such as increases in 
locomotor stereotypy and grooming behaviors (Ho et al., 2016). Together these 
findings suggest 5-HT1B receptor modulation may impact behavioral flexibility as 
well as locomotor activity.  
The current study examined the effects of acute, systemic administration 
of the 5-HT1B/1A receptor agonist RU24969 (0, 0.01, 0.1, and 1.0 mg/kg) in both 
male and female C57BL/6J mice. To examine the impact of 5-HT1B/1A receptor 
activation on behavioral flexibility mice were tested on a spatial probabilistic 
reversal learning task following administration of RU24969. It was predicted that 
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RU24969 would cause a dose-dependent impairment in spatial probabilistic 
reversal learning. Specifically, acute RU24969 administration at 0.01, 0.1, and 
1.0 mg/kg would significantly impair probabilistic reversal learning in C57BL/6J 
mice with 1.0 mg/kg eliciting the greatest impairment. To test this, all mice 
underwent an initial acquisition of spatial discrimination following vehicle 
treatment. Twenty-four hours later mice received either 0, 0.01, 0.1, or 1.0 mg/kg 
RU24969 before being tested on the reversal phase of a spatial probabilistic 
reversal learning task. The results from this task were used to determine if 
RU24969 impairs reversal learning performance in C57BL/6J mice. Previous 
studies utilizing RU24969 have found increased locomotor effects using relatively 
high doses of 1, 3, 5, and 10 mg/kg (Ho et al., 2016), as well as lower doses of 
0.625, 1.25, 2.5, and 5 mg/kg (McDougall et al., 2020). Since hyperlocomotion is 
considered to be an OCD-like behavior in rodents induced by activation of the 5-
HT1B receptor (Ho et al., 2016), it is important to understand whether the 5-
HT1B/1A agonist RU24969 administered at the low doses of 0.01, 0.1, or 1.0 
mg/kg induces hyperlocomotion. It was predicted that RU24969 will have a dose-
dependent increase in locomotor activity. To test this, mice were placed in an 
open field and recorded for one hour following injection of 0, 0.01, 0.1, 1.0 mg/kg 
RU24969. Total distance traveled as well as the percent time spent in the center 
of the open field versus the perimeter was recorded to determine potential 
treatment effects. It was also predicted that there would be a dose-dependent 
response for the percent time spent in the center of the open field. Specifically, 
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higher doses of RU24969 would decrease the percentage of time spent in the 
center. Finally, current research examining the sex differences in behavioral 
flexibility and locomotor activity with 5-HT1B/1A activation is scarce. Thus, this 
study aims to identify potential sex differences in behavioral flexibility and 
locomotor activity. It was predicted that male mice would become more impaired 








A total of 64 C57BL/6J mice (32 male, 32 female) were tested on the 
probabilistic reversal learning task and 64 C57BL/6J mice (32 male, 32 female) 
were used to assess locomotor activity in an open field. All mice were bred and 
housed at California State University, San Bernardino (CSUSB). Mice were 
housed in groups of four with same-sex littermates in plastic cages (28cm wide x 
17cm long x 12cm high) in a humidity (30%) and temperature (22-23 ° C) 
controlled room with a 12-hour light/dark cycle (lights on at 0700 hours) on a 
ventilated rack. For the probabilistic learning task, mice were food-restricted until 
reaching 85% of their free-feeding weight with no restrictions to water. Testing 
was completed in a separate room and during the animal’s light phase. Animal 
care and use was in accordance with the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals (2021) and was approved by the 
Institutional Laboratory Animal Care and Use Committee at CSUSB. All mice 
began testing at eight weeks of age. 
Treatment 
RU24969 (5-Methoxy-3-(1,2,5,6-tetrahydro-4-pyridinyl)-1H-indole) is a 
selective 5-HT1B agonist with a co-affinity for the 5-HT1A receptor (Aronsen et 
al., 2014). Mice were randomly assigned to receive either 0, 0.01, 0.1, or 1.0 
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mg/kg of the 5-HT1B/1A selective agonist RU24969 (Tocris Bioscience) 
dissolved in 50% DMSO solution. These doses were selected based on previous 
findings that show RU24969 can increase locomotor activity in mice and rats at 
doses between 0.625 and 10mg/kg (Ho et al., 2016; McDougall et al., 2020; 
Shanahan et al., 2009). Given that the probabilistic reversal learning task is a 
spatial task, low doses of 0.01, 0.1, and 1.0 mg/kg were chosen to prevent 
confounding effects in the spatial probabilistic reversal learning task of increased 
locomotion. Treatment was injected intraperitoneally (i.p.) at a 5 ml/kg injection 
volume. Control mice were injected with vehicle (50% DMSO). All mice received 
injections ten minutes before behavioral testing to ensure complete chemical 
metabolism. During the training days of the probabilistic reversal learning task, 
no injections were given.  
Behavioral Testing 
Spatial Probabilistic Reversal Learning 
The spatial probabilistic reversal learning task was conducted in three 
phases: spatial discrimination training, probabilistic acquisition, and probabilistic 
reversal learning. All phases of the probabilistic reversal learning task were 
conducted in a T-maze with equal-sized arms (36cm long x 12cm wide x 12cm 
tall). Once animals reached 85% of their free freed weight (4-6 days), they began 
spatial discrimination training. Mice required two to four days of training prior to 
testing of spatial acquisition. For spatial discrimination training, mice were placed 
in the starting arm of the T-maze closed by a guillotine door that was 
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perpendicular to the two choice arms. After one minute had elapsed, the start 
door was opened, and the mouse was allowed to freely navigate the choice arms 
and consume a ½ piece of cereal from a food well located at the end of each 
choice arm. The initial arm choice was recorded for each trial. After both cereal 
pieces were consumed, the start door was opened allowing the mouse to re-
enter the start area. The door was closed, the food wells re-baited, and the next 
trial began. This procedure was repeated for 15 minutes. Mice were considered 
habituated to the T-maze once they completed seven or more trials in a 15-
minute session across two consecutive days.  
Twenty-four hours after the mouse was trained, they began spatial 
acquisition in the same T-maze. Before the acquisition, every mouse was 
injected with the vehicle treatment. This was done to be consistent in mice 
receiving an injection before each test phase. At the beginning of the acquisition 
phase, each mouse was placed in the start area for one minute. Next, the door 
was opened allowing the mouse to choose between the two choice arms. Only 
one of the food wells was baited with a ½ cereal piece. Before testing, one arm 
was chosen as the “correct” spatial location and will contain a ½ piece of cereal 
on 80% of trials. The “incorrect” arm was baited during the other 20% of trials. 
The “correct” arm was animal-specific and was chosen based on the animal’s 
least initially chosen arm during training. This was done to ensure that animals 
are not choosing the arm out of habit from training. The first two trials were 
always be baited as “correct” choices. The learning criterion was considered 
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achieved when a mouse chose the “correct” arm for six consecutive trials. If a 
mouse chose the “correct” arm, it was allowed to consume the cereal piece and 
the guillotine door was raised allowing the mouse to return to the start area. If the 
“incorrect” arm was chosen, the mouse was allowed to investigate the un-baited 
food well, the start door was opened, and the mouse was returned to the start 
area. Every five trials, the maze was cleaned with a 10% alcohol and water 
solution to minimize the use of odor cues.  
Lastly, the reversal learning phase was conducted 24 hours following the 
acquisition phase. Ten minutes prior to testing, mice were injected with either 0, 
0.01, 0.1, or 1.0 mg/kg RU24969 to allow for complete chemical metabolism. 
Before reversal learning, a retention test was given to ensure that each mouse 
starts the reversal phase at a similar recall level from the discrimination learned 
in the acquisition phase. This means that mice were tested using the same 
“correct” and “incorrect” arm choices used during acquisition. The retention 
criterion was reached once the mouse successfully chooses the “correct” arm 
from acquisition on five out of six trials. Once the retention criterion was met, the 
reversal learning test immediately began. The reversal learning test was identical 
to the acquisition phase except the “correct” and “incorrect” arms were switched 
to the opposite arms respective to acquisition. For instance, if the “correct” arm 
choice was the left arm in the acquisition phase, the new “correct” arm choice in 
reversal was the right arm. The reversal criterion was met when mice made six 
consecutive correct choices. Both acquisition and reversal phases were timed on 
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a digital stopwatch. The treatment groups consisted of the following for both 
males and females: [acquisition-reversal] vehicle-vehicle (n=8), vehicle-RU24969 
0.01 mg/kg (n=8), vehicle-RU24969 0.1 mg/kg (n=8), and vehicle-RU24969 1.0 
mg/kg (n=8).  
The probabilistic reversal learning task required that a mouse choose one 
of the T-maze arms while considering previously made choices. To ensure that 
RU24969 at 0.01, 0.1, and 1.0 mg/kg did not induce hyperlocomotion, time-per-
trial was calculated (overall time divided by the number of trials) in minutes. Also, 
win-stay and lose-shift conditional probabilities were analyzed. A win-stay 
indicated when a mouse made a correct arm choice, received a food reward, and 
subsequently made another correct arm choice. A lose-shift indicated when a 
mouse made a correct arm choice but was not rewarded with food, and then 
choose the incorrect arm in the subsequent trial. If mice exhibited a high win-stay 
and a low lose-shift, it was more likely that the mouse was making deliberate 
choices. If there is a high win-stay and high lose-shift, meaning the mouse was 
simply chasing the food reward and not analyzing the probability aspect of 
making the arm choice that is baited 80% of the time, then it is more likely that 
the mouse was not making deliberate choices. This high win-stay high lose-shift 
scenario could suggest that RU24969 was inducing hyperlocomotion and the 
mouse was simply running through the maze and not learning the task itself. 
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Open Field Test 
Locomotor activity, as well as anxiety-like behavior, was measured using 
an open field. The open field was conducted in a square chamber with a solid 
white floor and black plastic walls (60 cm long x 60 cm wide x 30 cm in height). 
The testing chamber was divided into four equal quadrants to measure locomotor 
activity in four mice at a time in individual fields. Mice were tested for a total of 60 
minutes and recorded using Ethovision 3 video tracking system (Noldus, 
Leesburg, VA) to measure total distance traveled, time spent in the center, and 
time spent on the perimeter of the open field. To determine if RU24969 induced 
an anxiolytic-like effect, the percent time spent in the center of the open field was 
calculated by dividing the time spent in the center by the time spent in the center 
plus the time spent on the perimeter. Following the open field test trial, mice were 
placed back in their home cage and the open field was cleaned with a 10% 
alcohol solution. The treatment groups were as follows for male and female mice: 
vehicle (n=8), 0.01 mg/kg (n=8), 0.1 mg/kg RU24969 (n=8), and 1.0 mg/kg 
RU24969 (n=8).      
Statistical Analysis 
The effects of the 5-HT1B/1A receptor agonist RU24969 on reversal 
learning were analyzed utilizing separate two-way sex (female & male) by 
treatment (0, 0.01, 0.1, & 1.0 mg/kg RU24969) analyses of variance (ANOVAs) 
tests to determine potential sex and treatment differences. The trials to reach the 
criterion for the initial spatial acquisition, retention, and reversal learning tasks 
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were examined by separate two-way ANOVAs. Additionally, two-way (sex x 
treatment) ANOVAs were conducted to analyze perseverative errors, regressive 
errors, win-stay, and lose-shift conditional probabilities. To determine if locomotor 
activity had an effect on performance during the reversal learning task, locomotor 
activity was analyzed using a two-way sex by treatment (0, 0.01, 0.1, & 1.0 
mg/kg RU24969) ANOVA for the total distance traveled and percent time spent in 
the center of the open field. Dunnett post-hoc analyses were utilized when 
appropriate for multiple comparisons and statistical significance was determined 






Spatial Probabilistic Reversal Learning 
Performance on the acquisition phase was comparable between sex and 
treatment groups (Figure 1A). For acquisition, there was no main effect of sex 
[F(1,56) = 0.44, p = 0.51], treatment [F(3,56) = 0.49, p = 0.69], and no significant 
sex by treatment interaction [F(3,56) = 0.43, p = 0.74]. Also, retention of the initial 
acquisition phase was comparable between sex and treatment groups (Figure 
1C). There was no main effect of sex [F(1,56) = 0.48, p = 0.49], treatment 
[F(3,56) = 1.87, p = 0.15], and no significant sex by treatment interaction [F(3,56) 
= 0.81, p = 0.50] for trials to reach criterion. For reversal learning, there was no 
main effect of sex [F(1,56) = 2.10, p = 0.15] and no significant interaction 
between sex and treatment [F(3,56) = 1.93, p = 0.14] for trials to reach criterion. 
However, there was a main effect of treatment for trials to reach criterion during 
the reversal learning task [F(3,56) = 35.56, p < 0.001]. Separate Dunnett’s post 
hoc multiple comparisons were conducted for each sex and determined that 
there was no significant difference in trials to reach criterion for reversal learning 
in female mice treated with RU24969 at 0.01 mg/kg (p = 0.99) or 0.1 mg/kg (p = 
0.08) while female mice that were treated with the 1.0 mg/kg (p < 0.001) dose 
required significantly more trials to reach criterion for reversal learning compared 
to vehicle treated female mice. However, male mice treated with 0.01 (p = 0.04), 
0.1 (p < 0.001), or 1.0 (p < 0.001) mg/kg RU24969 all required significantly more 
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trials to reach criterion compared to vehicle treated male mice (Figure 1B). 
Therefore, RU24969 impaired reversal learning performance in female mice at 
the highest dose only (1.0 mg/kg) while performance was impaired for male mice 
at every dose. 
An analysis of errors committed by the mice was conducted to determine 
the effect of sex and treatment on perseverative errors, regressive errors, win-
stay probabilities, and lose-shift probabilities. There was no main effect of sex 
[F(1,56) = 0.27, p = 0.61] and no significant interaction [F(3,56) = 1.75, p = 0.17] 
between sex and treatment for perseverative errors. However, there was a main 
effect of treatment [F(3,56) = 10.49, p < 0.001] on perseverative errors 
committed. Post hoc Dunnett multiple comparisons conducted for each sex 
revealed that female mice treated with 1.0 (p < 0.001) mg/kg RU24969 
committed more perseverative errors compared to female vehicle controls. There 
was no significant difference in the number of perseverative errors committed in 
female mice treated with 0.01 (p = 0.99) or 0.1 (p = 0.24) mg/kg RU24969 
compared with female controls. Male mice treated with 1.0 (p = 0.03) mg/kg also 
committed significantly more perseverative errors than vehicle-treated males. 
Similar to the females, there was no significant difference in the number of 
perseverative errors committed between male mice treated with 0.01 (p = 0.63) 
or 0.1 (p = 0.06) mg/kg RU24969 and vehicle-treated males. Thus, RU24969 
treatment at 1.0 mg/kg impaired the ability to inhibit the previously learned spatial 
discrimination in both females and males (Figure 2A).  
37 
 
Regressive errors showed a similar trend in that there was no main effect 
of sex [F(1,56) = 0.71, p = 0.40] and no significant interaction between sex and 
treatment [F(3,56) = 0.98, p = 0.41]. There was a significant main effect of 
treatment on regressive errors [F(3,56) = 5.76, p < 0.01]. Dunnett post hoc 
multiple comparisons for each sex revealed that there was no significant 
difference between the number of regressive errors committed for female 
controls and females treated with 0.01 (p = 0.99), 0.1 (p = 0.93), or 1.0 (p = 0.25) 
mg/kg RU24969. However, male mice treated with 1.0 mg/kg RU24969 
committed significantly more regressive errors compared to vehicle treated males 
(p < 0.001). There were no significant differences in regressive errors committed 
between vehicle treated males and males treated with 0.01 (p = 0.83) or 0.1 (p = 
0.13) mg/kg RU24969. Thus, RU24969 treatment at 1.0 mg/kg reduced the 
ability to maintain the new choice pattern once it was selected in males only 
(Figure 2B).   
Finally, win-stay and lose-shift probabilities were analyzed. For win-stay 
errors, there was no main effect of sex [F(1,56) = 1.23, p = 0.27] or treatment 
[F(3,56) = 2.23, p = 0.10], and no significant interaction between sex and 
treatment [F(3,56) = 0.42, p = 0.74] (Figure 3A). Similarly, for lose-shift 
probabilities, there was no main effect of sex [F(1,56) = 1.68, p = 0.20] or 
treatment [F(3,56) = 0.80, p = 0.50], and no significant interaction between sex 
and treatment [F(3,56) = 0.67, p = 0.57] (Figure 3B).  
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Open Field Test 
A two-way ANOVA with sex (female & male) by treatment (0, 0.01, 0.1, 
1.0 mg/kg RU24969) analysis was conducted to determine mean differences in 
total distance travelled as well as the percent of time spent in the center of the 
open field. Analysis revealed a significant main effect of treatment on total 
distance traveled [F(3,56) = 6.21, p = 0.001] and no significant main effect of sex 
[F(1,56) = 0.06, p = 0.80] or interaction between sex and treatment [F(3,56) = 
0.89, p = 0.45]. Dunnett post hoc analysis conducted for each sex revealed that 
there was no significant difference in total distance travelled between female 
mice treated with 0.01 (p = 0.59), 0.1 (p = 0.33), or 1.0 (p = 0.63) mg/kg 
RU24969 and vehicle treated females. However, males treated with 1.0 mg/kg 
RU24969 exhibited less locomotor activity in the open field compared to vehicle 
treated males (p = 0.007). Males treated with 0.01 (p = 0.99) and 0.1 (p = 0.12) 
mg/kg RU24969 demonstrated similar locomotor activity to vehicle treated males. 
Overall, RU24969 only impaired locomotor activity in males treated with 1.0 
mg/kg RU24969 and had no effect on females (Figure 4A). 
When analyzing anxiety-like behaviors in the open field test, the analysis 
showed a significant main effect of treatment on percent time spent in the center 
of the open field [F(3,56) = 8.57, p < 0.001], although, there was no main effect of 
sex [F(1,56) = 1.74, p = 0.19]. Dunnett multiple comparisons conducted for each 
sex revealed that there was no significant difference between the percentage of 
time spent in the center of the open field for female mice treated with 0.01 (p = 
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0.21), 0.01 (p = 0.99), or 1.0 (p = 0.99) mg/kg RU24969 and vehicle-treated 
female mice. Although, male mice treated with 0.1 (p = 0.002) and 1.0 (p < 
0.001) mg/kg RU24969 spent significantly less percentage of time in the center 
of the open field compared to vehicle-treated males (Figure 4B). There was also 
a significant interaction between sex and treatment for time spent in the center of 
the open field [F(3,56) = 4.69, p = 0.005]. Using Bonferroni multiple comparisons, 
it was determined that male mice treated with vehicle spent a greater percentage 
of their time in the center of the open field compared to female mice treated with 
vehicle (p = 0.003). However, there were no significant differences between the 
percent of time spent in the center of the open field between female and male 
mice treated with 0.01 (p = 0.99), 0.1 (p = 0.99), or 1.0 (p = 0.44) mg/kg 
RU24969.  Overall, male mice that received the two highest doses of 0.1 and 1.0 
mg/kg RU24969 spent less time in the center of the open field compared to male 
mice that received vehicle treatment. RU24969 did not affect the percentage of 
time spent in the center of the open field in female mice. While the interaction 
between sex and treatment for percent time spent in center was significant, there 
was only a significant difference in the percentage of time spent in the center of 
the open field between females and males that were treated with vehicle while 







Figure 1.  Trials to Reach Criterion for Acquisition, Reversal, and Retention 
 
A) Trials to reach the criterion for the initial spatial acquisition task were similar 
between all treatment groups for both female and male C57BL/6J mice. All mice 
were treated with vehicle (VEH) ten minutes before testing on the acquisition 
phase. B) Female mice that received 1.0 mg/kg RU24969 required more trials to 
reach the criterion compared to vehicle-treated females. Male mice that received 
0.01, 0.1, or 1.0 mg/kg RU24969 required more trials to reach criterion compared 
to vehicle-treated males. Reversal learning was measured immediately following 
retention. C) Trials to reach the criterion for retention were similar across all 
treatment groups for both females and males. Retention of the initial spatial 
acquisition was tested before the reversal learning phase and ten minutes before 







Figure 2.  Perseverative and Regressive Errors Committed 
 
A) RU24969 increased perseverative errors in both female and male mice. 
Perseverative errors committed were similar for both females and males that 
received 0.01 or 0.1 mg/kg RU24969 compared to same-sex vehicle-treated 
mice. B) Male mice treated with 1.0 mg/kg RU24969 committed more regressive 
errors compared to vehicle-treated male mice. Regressive errors committed were 
similar for male mice treated with 0.01 and 0.1 mg/kg RU24969 compared to 
vehicle-treated males. For the females, there was no difference between the 
number of regressive errors committed between all doses. *p < 0.05, **p < 0.01 






Figure 3.  Win-Stay and Lose-Shift Conditional Probabilities 
 
A) Female nor male mice expressed differing win-stay probabilities. B) Female 






Figure 4.  Open Field Test of Locomotor Activity and Anxiety-Like Behavior 
 
A) Male mice that received 1.0 mg/kg RU24969 had reduced locomotor activity 
compared to vehicle-treated males. There was no difference in locomotor activity 
between males that received 0.01 or 0.1 mg/kg RU24969 and vehicle-treated 
males. There was no difference in locomotor activity between female treatment 
groups. B) Male mice that received 0.1 or 1.0 mg/kg RU24969 spent less time in 
the center of the open field compared to vehicle-treated males. Males treated 
with 0.01 mg/kg RU24969 spent a similar amount of time in the center of the 
open field compared to vehicle-treated males. There was no difference in time in 
the center between female treatment groups. **p < 0.01 vs. vehicle within the 







The current experiment examined the effects of simultaneous 5-HT1B and 
5-HT1A receptor activation on behavioral flexibility, locomotor activity, and 
anxiety-like behavior in C57BL/6J mice. It was originally hypothesized that 
activation of 5-HT1A and 5-HT1B receptors would elicit a dose-dependent 
impairment in behavioral flexibility at 0.01, 0.1, and 1.0 mg/kg. Overall findings 
suggest that RU24969 elicited a dose-dependent response in male mice at 0.01, 
0.1, and 1.0 mg/kg impairing behavioral flexibility as shown by an increase in 
trials to reach criterion compared to vehicle-treated controls. Impairments in 
behavioral flexibility were only observed in female mice that received the highest 
dose of 1.0 mg/kg RU24969. Both female and male mice that received 1.0 mg/kg 
RU24969 also exhibited more perseverative errors compared to vehicle-treated 
controls. Regardless of sex, the highest dose led to an inability to inhibit the initial 
choice pattern established during acquisition. Although, only male mice treated 
with 1.0 mg/kg RU24969, demonstrated more regressive errors compared to 
vehicle-treated controls.  
It was also hypothesized that locomotor activity would be significantly 
increased by RU24969 at 0.01, 0.1, or 1.0 mg/kg. Results showed that only male 
mice treated with 1.0 mg/kg RU24969 exhibited reduced locomotor activity when 
compared to vehicle-treated males. Finally, it was predicted that there would be a 
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dose-dependent reduction in the percentage of time mice spent in the center of 
an open field for 0.01, 0.1, and 1.0 mg/kg RU24969. It was determined that 
RU24969 at 0.1 and 1.0 mg/kg reduced the percentage of time male mice spent 
in the center of an open field and had no effect on female C57BL/6J mice. In 
addition, vehicle-treated males spent a greater percentage of time in the center 
of the open field compared to vehicle-treated females. Thus, RU24969 at the two 
higher doses increased anxiety-like behaviors in only male C57BL/6J mice.   
Spatial Probabilistic Reversal Learning 
As we have previously found, mice treated with the vehicle on acquisition 
showed comparable trials needed to reach criterion in male and female 
C57BL/6J mice (Amodeo et al., 2012, Amodeo et al., 2019). Thus, all mice were 
comparable on the acquisition of the spatial discrimination before moving onto 
the reversal phase. Male mice treated with 0.01, 0.1, and 1.0 mg/kg RU24969 
displayed deficits in behavioral flexibility. RU24969 treated male mice required 
more trials to reach completion criterion in the spatial probabilistic reversal 
learning task compared to vehicle-treated male mice. It has previously been 
established that 5-HT1A receptor activation using 8-OH-DPAT reduced 
alternation ratios in male C57BL/6J mice, thus increasing behavioral rigidity 
(Odland, Jessen, Fitzpatrick, et al., 2019; Odland, Jessen, Kristensen, et al., 
2019). In addition, 8-OH-DPAT has been shown to increase compulsive-like 
checking behavior in male rats (Alkhatib et al., 2013). Together, 5-HT1A 
activation contributes to an increase in compulsive-like behaviors in male rodents 
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and may explain the increase in trials to reach criterion with RU24969 treatment 
male mice, but also the increase in perseverative and regressive errors.  
 In the current study, both female and male mice treated with 1.0 
mg/kg RU24969 committed more perseverative errors than same-sex controls 
while only male mice treated with 1.0 mg/kg RU24969 committed more 
regressive errors. Regardless of sex, the highest dose tested led to an impaired 
ability to inhibit the previously learned discrimination when contingencies were 
reversed. Thompson and Dulawa (2019) similarly found that RU24969 led to 
perseverative locomotor patterns. This inability to flexibly adapt in the face of 
changing reward contingencies can be found in OCD individuals (Deepthi et al., 
2021). To our knowledge, this is the first study that has looked at the direct 
effects of acute RU24969 administration on behavioral flexibility in both female 
and male mice.  
Open Field Test 
The current study found that simultaneous activation of 5-HT1B and 1A 
receptors using RU24969 reduced locomotor activity in male mice treated with 
1.0 mg/kg. RU24969 did not influence locomotor activity for female mice at any 
dose. Although, previous research has demonstrated the opposite effect using 
RU24969. Locomotor activity has been shown to be increased in female 
C57BL/6J mice using RU24969 at 1.0, 3.0, 5.0, and 10.0 mg/kg (Ho et al., 2016), 
while we did not find a significant change in female mice treated with 1.0 mg/kg. 
Another study testing the much higher 10.0 mg/kg RU24969 dose found an 
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increase in locomotor activity over 20 minutes in an open field test in male mice 
(O’Reilly et al., 2021). Interestingly, preweaning female and male Sprague 
Dawley rats treated with 0.625, 1.25, 2.5, or 5.0 mg/kg RU24969 exhibited 
increased locomotor activity compared to controls (McDougall et al., 2020, 2021), 
which may highlight possible maturation changes in 5-HT1B/1A receptor 
functioning.  
Past research has also shown that activation of 5-HT1B receptors with 
several different compounds at 3.0 and 30.0 mg/kg doses increased locomotor 
activity in male mice (O’Neill et al., 1997). Another study found no change in 
locomotor activity following a 5.0 mg/kg injection of RU24969 using male 5-HT1B 
knockout mice (Malleret et al., 1999). This suggests that the 5-HT1B receptor is 
responsible for changes in locomotor activity. A possible explanation for the 
contrasting results between previous research and the current study is that mice 
treated with high doses of a 5-HT1B/1A agonist respond with increased 
locomotor activity while lower doses like the ones used in the present study have 
the opposite effect and reduce locomotor activity. These paradoxical findings 
highlight the need to further investigate the effects of 5-HT1B and 5-HT1A 
activation on locomotor activity using a wide range of doses to get a clear 
understanding of the associated dose-dependent response.  
Anxiety-like behaviors were also measured in the open field test. Male 
mice that received 0.1 and 1.0 mg/kg RU24969 spent less time in the center of 
the open field suggesting that simultaneous activation of 5-HT1B and 1A 
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receptors increases anxiety-like behaviors in males only. One previous study 
showed no change in anxiety-like behaviors using RU24969 in food or water 
motivated conflict tests (Gardner, 1986). In tasks such as the Vogel conflict 
drinking test and elevated plus-maze test, 5-HT1B receptor activation using 
CP94253 resulted in anxiolytic-like effects in male mice (Tatarczyńska et al., 
2004). A 5-HT1B antagonist SB 224289 was found to have anxiogenic-like 
effects in male rats as evidenced by an increase in latency to leave the starting 
area of an open field compared to controls (Hoplight et al., 2005). These findings 
suggest that 5-HT1B receptors indeed modulate anxiety-like behaviors and that 
activation of 5-HT1B should reduce anxiety while blockade should increase 
anxiety. Instead, we found competing results. The reduced percentage of time 
spent in the center of the open field observed following RU24969 treatment could 
be the result of an overall reduction in locomotor activity. Thus, male mice spent 
less time exploring the center of the open field compared to the perimeter 
because locomotor activity was significantly reduced in males as well, therefore 
further studies are needed.  
A limitation of the present study is the lack of co-administration of a 5-
HT1A or 1B receptor antagonist with RU24969 in hopes of teasing out the effects 
of specific receptor activation. Co-administration of a 5-HT1A or 1B receptor 
antagonist would highlight the specific receptor effects on probabilistic reversal 
learning. In addition, we need to consider whether the increase in anxiety-like 
behaviors was simply the result of reduced locomotor activity. The inclusion of 
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other measures of anxiety, such as the elevated plus-maze, needs to be tested 
and compared alongside the open field test using the same doses of RU24969 to 
determine if the anxiogenic effect found in the current study was due to increased 
anxiety or reduced locomotion.  
Conclusion 
The present study sought to understand whether simultaneous activation 
of 5-HT1B and 1A receptors using the 5-HT1B/1A receptor agonist RU24969 
would elicit OCD-like behaviors in mice. The OCD-like behavioral inflexibility was 
examined by applying a spatial probabilistic reversal learning task while 
locomotor activity and anxiety-like behaviors were also measured in the open 
field. Results showed that RU24969 impaired reversal learning in both females 
and males suggesting that activation of 5-HT1B and 1A receptors induces the 
OCD-like symptom of behavioral inflexibility. Administration of RU24969 resulted 
in reduced locomotor activity as well as increased anxiety-like behaviors in male 
mice. These findings suggest that 5-HT1B and 1A receptor activation increases 
anxiety in male mice. Overall, the evidence suggests that 5-HT1A and 1B 
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